Table 1.
Characteristics of the studies included in this meta-analysis.
| Author, year | n | Type of animal | Type of injury | MSC type | Number of MSC | Route of delivery | Endpoints for this meta-analysis |
|---|---|---|---|---|---|---|---|
| Herrera 2004 | 24 | Mice | Glycerol-induced | BM-MSCs | 1 × 106 | Intravenous injection | Scr |
| Bi 2007 | 12 | Mice | Cisplatin-induced | BM-MSCs | 2 × 105 | Intravenous injection or intraperitoneal injection | Scr, BUN |
| Sun 2008 | 40 | Rat | Glycerol-induced | BM-MSCs | 2 × 106 | Abdominal aorta injection | Scr, BUN |
| Qian 2008 | 6 | Rat | Glycerol-induced | BM-MSCs | 1 × 104 | Intravenous injection | Scr |
| Magnasco 2008 | 22 | Rat | Adriamycin-induced | BM-MSCs | 3 × 106 | Intravenous injection | Scr, BUN, UAE, renal damage score |
| Bruno 2009 | 16 | Mice | Glycerol-induced | BM-MSCs | — | Intravenous injection | Scr, BUN, MDA, GSH, SOD, renal damage score |
| Eliopoulos 2010 | 10 | Mice | Cisplatin-induced | BM-MSCs | 5 × 106 | Intraperitoneal injection | Scr, BUN |
| Kim 2012 | 17 | Rat | Cisplatin-induced | AD-MSCs | 5 × 105 | Intravenous injection | Scr, BUN |
| Zickri 2012 | 30 | Rat | Adriamycin-induced | hUC-MSCs | 5 × 105 | Intravenous injection | Scr |
| Sarhan 2014 | 19 | Rat | Adriamycin-induced | BM-MSCs | 4 × 106 | Intravenous injection | Scr, BUN, UAE, renal pathology, MDA, GSH |
| Moustafa 2016 | 80 | Rat | Cisplatin-induced | BM-MSCs | 5 × 106 | Intravenous, intraarterial or kidney subcapsular injection | Scr, MDA, GSH, SOD |
| Elhusseini 2016 | 40 | Rat | Cisplatin-induced | AD-MSCs | 5 × 106 | Intravenous injection | Scr, BUN, Ccr, renal pathology, MDA, GSH, SOD |
| Anan 2016 | 13 | Rat | Adriamycin-induced | BM-MSCs | 1 × 106 | Intravenous injection | Scr, BUN, SOD |
| Gad 2017 | 24 | Rat | Methotrexate-induced | BM-MSCs | 2 × 106 | Intraperitoneal injection | Scr, BUN, MDA, GSH |
| Rashed 2018 | 20 | Rat | Streptozotocin -induced | BM-MSCs | 1 × 106 | Intravenous injection | Scr, BUN, UAE, Ccr |
| Elbaghdady 2018 | 20 | Rat | Cadmium chloride-induced | BM-MSCs | 2 × 106 | Intravenous injection | Scr |
| Danjuma 2018 | 16 | Rat | Rifampicin-induced | BM-MSCs | 2.5 × 105 | Intravenous injection | Scr, BUN |
| Putra 2019 | 10 | Rat | Gentamicin induced | hUC-MSCs | 1 × 106 | Intraperitoneal injection | Scr, BUN, renal pathology |
| Cetinkaya 2019 | 17 | Rat | Aristolochic acid induced | hAMSC | 6 × 105 | Intravenous injection | Scr, BUN |
| Selim 2019 | 70 | Rat | Cisplatin-induced | AD-MSCs; BM-MSCs | 4 × 106 | Intravenous injection | Scr, BUN |
| Mata-Miranda 2019 | 10 | Mice | Cisplatin-induced | mESCs | 1 × 106 | Intraperitoneal injection | Scr |
| Vazquez-Zapien 2019 | 19 | Mice | Cisplatin-induced | mESCs | 1 × 106 | Intraperitoneal injection | Scr |
| Minocha 2019 | 3 | Rat | Cisplatin-induced | AFSC | 2 × 106 | Intravenous injection | Scr, BUN |
| Sun B 2019 | 10 | Rat | Cisplatin-induced | USCs | 2 × 106 | Intravenous injection | Scr |
| Sun 2019 | 6 | Rat | Cisplatin-induced | BM-MSCs | — | Renal parenchyma injection | Scr, BUN |
| Zhang 2020 | 9 | Rat | Cisplatin-induced | USCs | 5 × 106 | Subcutaneous injection | Scr, Ccr, renal pathology |
| Foroutan 2020 | 6 | Rat | Cisplatin-induced | BM-MSCs | — | Intraperitoneal injection | Scr, BUN |
Note: BM-MSCs: bone marrow mesenchymal stem cells; hAMSCs: human amnion-derived mesenchymal stem cells; hUC-MSCs: human umbilical cord-mesenchymal stem cells; AD-MSCs: adipose tissue-derived mesenchymal stem cells; mESCs: mouse embryonic stem cells; AFSCs: amniotic fluid stem cells; USCs: urine-derived stem cells; Scr: serum creatinine; BUN: blood urea nitrogen; UAE: urinary albumin excretion; Ccr: creatinine clearance rate; MDA: malondialdehyde; GSH: L-glutathione; SOD: superoxide dismutase.